Combination Therapy with Remdisivir and Tocilizumab for COVID-19: Lessons for Futures Studies
| Author | Hamideh Abbaspour Kasgari | en |
| Author | Farhang Babamahmoodi | en |
| Author | Ali Reza Davoudi Badabi | en |
| Author | Ali Abbaskhani Davanloo | en |
| Author | Parisa Moradimajd | en |
| Author | Hamidreza Samaee | en |
| Orcid | Parisa Moradimajd [0000-0003-3648-8979] | en |
| Orcid | Hamidreza Samaee [0000-0002-6906-0816] | en |
| Issued Date | 2020-06-20 | en |
| Abstract | The outbreak of (SARS-CoV-2) originated in Wuhan, China, and pneumonia induced by this virus is named coronavirus disease 2019 (Covid-19). By March 29, 2020, 737000 people were infected and 35000 died worldwide. To date, no effective medication is recommended to treat SARS-CoV-2 infection, and the drugs introduced are still in the clinical trial phase. Tocilizumab and Remdisivir are possible drugs to treat and improve the symptoms of the patients. We prescribed a combination of Remdisivir and Tocilizumab to treat three critical patients with Covid-19, and presented the results in this article. After the duration of treatment with this combination, one case was improved and discharged, but, unfortunately, two cases expired. | en |
| DOI | https://doi.org/10.5812/archcid.103537 | en |
| Keyword | Remdisivir | en |
| Keyword | Tocilizumab | en |
| Keyword | COVID-19 | en |
| Keyword | Corona Virus | en |
| Publisher | Brieflands | en |
| Title | Combination Therapy with Remdisivir and Tocilizumab for COVID-19: Lessons for Futures Studies | en |
| Type | Case Report | en |